| Gene symbol | CD5 | Synonyms | LEU1, T1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD5 molecule | ||||
| GTO ID | GTC3807 |
| Trial ID | NCT06316856 |
| Disease | T-Cell Acute Lymphocytic Leukemia |
| Altered gene | CD5 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD5 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | CD5 Chimeric Antigen Receptors (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: a Single-center, Open-label, Non-randomized, Phase 1/2 Clinical Trial |
| Year | 2024 |
| Country | China |
| Company sponsor | Beijing GoBroad Hospital |
| Other ID(s) | BJGBYY-IIT-LCYJ-2024-002 |
| Cohort 1 | |||||||||||
|
|||||||||||